US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,715.28

-3.7474-0.22%

Number of Gainers:- -

Number of Losers:1

Number of Flat:1

PE:- -

High:1,730.47

Open:1,728.65

Low:1,714.24

Close:1,719.02

Volume:8.44M

Turnover:1.21B

Market Cap:441.97B

Float Cap:433.77B

Loading ...

Novartis India Hits Record High on Retina Drugs Distribution Deal, Pfizer Brand Acquisition

Stocks to Watch: Amgen, Nike, Bloom Energy

Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints

Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks

Novartis Might Need More Deals to Deliver Growth Ambitions

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Novartis's Latest Trial Setback Sinks Stock

Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell

MT Newswires Live

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday

Benzinga Earnings

Novartis's Latest Trial Failure is Second Pipeline Setback in a Row

European Equities Remain Flat as Energy Gains Offset by Pharma Slump

Gilead Sciences (GILD) Receives a Buy from Bernstein

Novartis AG Falls Monday, Underperforms Market

Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321

Citi sees limited immediate downside for Ionis after pelacarsen failure

BofA sees low single-digit percentage downside for Novartis on pelacarsen miss

Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial

Novartis India to Acquire 'Minipress' Trademarks from Pfizer

Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares

Novartis Heart-Trial Failure Could be Mitigated by Investor Caution

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/BK4578/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1715.2769,"timestamp":1789070399999,"preClose":1719.0243,"halted":0,"volume":8441319,"delay":0,"changeRate":-0.00218,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-3.747437,"latestTime":"09-10 16:00:00 EDT","open":1728.6481,"high":1730.4697,"low":1714.2401,"amount":1205745785.930958,"amplitude":0.009441,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.314749,"peRate":46.628821,"turnoverRate":0.002733,"increases":0,"decrements":1,"flats":1,"marketCap":441974652928,"floatMarketCap":433773854720},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1730.4697,"amplitude":0.009441,"preClose":1719.0243,"low":1714.2401,"pbRate":"8.314749","latestPrice":1715.2769,"volume":8441319,"delay":0,"open":1728.6481,"prevYearClose":1612.5378,"prevWeekClose":1911.2454,"prevMonthClose":1830.2803,"prevQuarterClose":1768.1697,"fiveDayClose":1922.4193,"twentyDayClose":1781.5829,"sixtyDayClose":1720.4836,"secType":"PLATE","market":"US","turnoverRate":0.002733,"peRate":46.628821,"marketCap":441974652928,"floatMarketCap":433773854720,"timestamp":1789070399999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":0,"down":1,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665326663","title":"Novartis India Hits Record High on Retina Drugs Distribution Deal, Pfizer Brand Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326663","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326663?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:12","pubTimestamp":1788858752,"startTime":"0","endTime":"0","summary":"BUZZ-Novartis India hits record high on retina drugs distribution deal, Pfizer brand acquisition** Shares of Novartis IndiaNOIN.BOjump as much as 12.9% to a record high of 1,850.95 rupees** NOIN enters into an exclusive promotion and distribution agreement with Novartis Healthcare to market its retina portfolio in India** Under the deal, NOIN will exclusively distribute Accentrix and Pagenax in India, marking its entry into ophthalmology, and will pay NHPL an upfront fee of 100 million rupees ** On Monday, Novartis India said that it will acquire the Minipress brand and related IP from PfizerPFE.Nfor about 12.5 billion rupees** Pfizer IndiaPFIZ.NSwill stop selling Minipress XL and receive $13.9 million from the parent; the drug is used to treat hypertension and BPH-related urinary symptoms** YTD, NOIN up ~137%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4500KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE0002141913.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0320765489.SGD","PPH","LU0211331839.USD","NVS","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4532","MEDX","BK4007","IE00B2B36J28.USD","LU0070302665.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","BK4588","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342326","title":"Stocks to Watch: Amgen, Nike, Bloom Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665342326?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:07","pubTimestamp":1788858420,"startTime":"0","endTime":"0","summary":"Amgen : Shares of the biotechnology company, a major contributor to the Dow, shed more than 5% premarket after the Swiss drugmaker Novartis  said an experimental medicine failed to reduce cardiovascular risk in a late-stage clinical trial. Amgen and Eli Lilly  are working on rival treatments. Novartis shares tumbled 10% in Europe, while Eli Lilly shares ticked down.Bloom Energy : The fuel-cell maker is among the companies that will join the S&P 500 later this month, S&P Dow Jones Indices announced late Friday, sending its shares 4% higher premarket. Meanwhile, Nike  will be deleted from the S&P 100. Its shares edged lower premarket.Coinbase Global , Robinhood Markets , Strategy : Shares of companies tied to cryptocurrencies retreated in premarket trading as bitcoin's price slipped more than 1% to trade below $78,500.GameStop  is set to report earnings after markets close.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","04332","LU2089984988.USD","BK4558","COIW","LU1988902786.USD","LU2468319806.SGD","SMST","MEDX","HOOW","BK4578","COIA","09311","LU2294711713.HKD","BK4585","LU1861559042.SGD","SG9999001440.SGD","AMGN","FINX","CONL","IE00B4R5TH58.HKD","LU1642822529.SGD","GMEC","LU0070302665.USD","09399","GMEY","09711","07799","BK4127","LU1267930227.SGD","LU1861220207.SGD","LU1983299246.USD","LU0786609619.USD","BK4595","MTYY","LU0823414551.USD","BK4577","IMST","MSTK","SIMS","PBE","LU0320765489.SGD","APED","IBB","LU2098885051.SGD","BK4007","LU0211331839.USD","BK4146","HOOC","WATS","SMOG","VCLN","LMI3.UK","LU2242646821.SGD","BK4023","HOOD","BLCK","VTWG","HOOG","LU2357125470.USD","TBXU","LU0823414478.USD","COIN","LU0109394709.USD","CTEC","BEG","HOOZ","IE0009355771.USD","BK4541","LU1267930573.SGD","BK4532","LU0128525689.USD","BK4076","COIG","IE00BYQQ9H92.USD","ZAP","IE00BFTCPJ56.SGD","LU0310800379.SGD","WNTR","BK4566","LU0052756011.USD","LU0058720904.USD","LU0476273544.USD","MSDD","BK4581","HOYY","IE00BJT1NW94.SGD","HOOI","IBAT","ICOI","HOOY","MSTP","CONI","MSTR","FRNW","HOII","LU0320765992.SGD","LU1057294990.SGD","MSST","IAI","MSTZ","IE0002141913.USD","07311","BK4596","ICLN","LU0029864427.USD","MSTY.UK","LU0708994859.HKD","LU0823411888.USD","DAPP","IBLC","LU0868494617.USD","BITQ","BK4516","GMEU","BIB","CONY","LU0128525929.USD","BE","GME","BK4112","CNRG","STYL","LU1815336760.USD","LU1861558580.USD","BK4588","HODU","BEZ","IBBQ","LU0310800965.SGD","BBH","FIAT","LU0792757196.USD","LU1267930813.SGD","IE00BJJMRZ35.SGD","LU0444971666.USD","07711","MST","MSTY","LU0889565916.HKD","LU2360107671.USD","PJP","MSTC","BK4547","OWNB","BK4535","BK4561","UPGR","LU0208291251.USD","MSTU","IGME","LU1571399168.USD","LU0957808578.USD","COIO","BK4534","NKE","MSII","COIX","MSOO","IE00BFXG0V08.USD","LU1303367103.USD","BK4539","BK4599","BK4182","HOOX","BK4600","LU1064131342.USD","LU0444973449.USD","LU2264538146.SGD","MSTX","LU1861217088.USD","BK4139","BEC","BEX","BPAY","CONX","LU0289739699.SGD","SMI3.UK","3SMI.UK","LU0889566641.SGD","LU2242652126.USD","BK4533","MSTW","NVS","09799","BKCH","COII","EGGY","LU2112291526.USD","BK4554","LU1061106388.HKD","FDIG","CRPT","3LMI.UK","COYY","07399","LU1023059063.AUD","IE0009354923.USD","LU2506951792.HKD","LU0122379950.USD","LU2543165471.USD","PPH","BK4551","LU2249611893.SGD","ROBN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665261713","title":"Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2665261713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665261713?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:03","pubTimestamp":1788858204,"startTime":"0","endTime":"0","summary":"Novartis ($NVS) stock plunged about 13% in Tuesday’s pre-market trading as the Swiss drugmaker’s experimental drug, del-desiran, for a muscle-wasti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novartis-stock-nvs-sinks-on-another-setback-muscle-wasting-disorder-drug-disappoints?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novartis-stock-nvs-sinks-on-another-setback-muscle-wasting-disorder-drug-disappoints?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4588","IE0002141913.USD","BK4578","PPH","NVS","BK4532","LU0320765489.SGD","IE00BJJMRZ35.SGD","LU0208291251.USD","IE0009355771.USD","MEDX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0070302665.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125754221","title":"Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks","url":"https://stock-news.laohu8.com/highlight/detail?id=1125754221","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125754221?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:00","pubTimestamp":1788858037,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical heavyweight Novartis faced a turbulent trading session on Tuesday as its shares tumbled sharply following the disclosure that its experimental drug for muscular dystrophy,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","IE0002141913.USD","BK4578","IE00BJT1NW94.SGD","LU0208291251.USD","BK4007","LU0070302665.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4532","PPH","BMED","MEDX","BK4585","PSYK","LU0211331839.USD","BK4588","IE00B2B36J28.USD","LU0320765489.SGD","IBBJ","IE0009355771.USD","MDTX","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323400","title":"Novartis Might Need More Deals to Deliver Growth Ambitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323400?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:17","pubTimestamp":1788855420,"startTime":"0","endTime":"0","summary":"0817 GMT - Novartis's latest clinical-trial failure suggests the company might need more dealmaking to deliver on its ambition for steady growth beyond 2030, Jefferies analysts say in a research note. The Swiss drugmaker maintained its 2025-30 sales guidance as it said its neuromuscular drug del-desiran missed the main goal in a late-stage study. However, no comment was provided on the ambition to grow by mid-single percentage digits beyond 2030, the analysts say. Even with the recent success of a new multiple-sclerosis pill, it will be challenging to get confidence on the company's growth for the 2030s without del-desiran and del-brax, two drugs Novartis acquired from Avidity Biosciences, Jefferies says. As a result, dealmaking will likely remain part of Novartis's story, the analysts add. Shares fall 10%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","PPH","NVS","IE00B4R5TH58.HKD","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4588","LU0070302665.USD","BK4585","LU0208291251.USD","IE00B2B36J28.USD","BK4578","BK4007","IE00BJJMRZ35.SGD","MEDX","LU0211331839.USD","IE0002141913.USD","BK4532","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532340","title":"Why the Dow is Being Dragged Down by a Swiss Company's Bad News","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532340?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:15","pubTimestamp":1788855300,"startTime":"0","endTime":"0","summary":"Bad news from Swiss pharmaceutical giant Novartis was weighing on the Dow on Tuesday.Investors returning from the Labor Day break could be forgiven for wondering if their eyes were deceiving them, but","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4139","LU0058720904.USD","SG9999001440.SGD","BK4599","LU2089984988.USD","LU0889565916.HKD","NVS","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0109394709.USD","BK4533","IE00B4R5TH58.HKD","BK4578","LU2468319806.SGD","LU0122379950.USD","BK4007","LU1983299246.USD","IBB","PBE","TBXU","LU0868494617.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","MEDX","LU0211331839.USD","BBH","LU1057294990.SGD","LU2112291526.USD","BK4532","BK4585","IE00B2B36J28.USD","PPH","LU0208291251.USD","LU1061106388.HKD","BK4588","LU0320765489.SGD","IE0009355771.USD","AMGN","PJP","LU0320765992.SGD","LU1023059063.AUD","BK4566","LU0070302665.USD","BK4534","NAMS","LU2242652126.USD","BK4581","IBBQ","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323985","title":"Novartis's Latest Trial Setback Sinks Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323985","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323985?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:01","pubTimestamp":1788854460,"startTime":"0","endTime":"0","summary":"Novartis shares plunged after the Swiss drugmaker said an experimental neuromuscular medicine missed the primary goal in a late-stage clinical trial, the latest blow to its efforts to find new growth ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPH","LU0208291251.USD","BK4532","LU0070302665.USD","LU0211331839.USD","BK4585","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4588","IE00BJJMRZ35.SGD","BK4007","MEDX","IE00B2B36J28.USD","IE0009355771.USD","LU0320765489.SGD","BK4578","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323534","title":"Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323534","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323534?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:58","pubTimestamp":1788854332,"startTime":"0","endTime":"0","summary":"Novartis  said Tuesday its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time.The drug candidate for the genetic muscular disorder displayed signs of clinical activity for its secondary endpoints measuring muscle strength, daily living activities, and mobility during the trial, the company said.The company is analyzing the full dataset to decide future development plans while maintaining its five-year annual sales growth target of 5% to 6% through 2030, Novartis said.Shares of the company were down by more than 13% in Tuesday premarket activity.Price: 138.80, Change: -21.19, Percent Change: -13.24","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4588","MEDX","IE00B4R5TH58.HKD","BK4585","IE0009355771.USD","IE00B2B36J28.USD","LU0211331839.USD","LU0070302665.USD","PPH","NVS","BK4578","LU0208291251.USD","BK4532","IE00BJJMRZ35.SGD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665402063","title":"United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2665402063","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665402063?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:11","pubTimestamp":1788851511,"startTime":"0","endTime":"0","summary":"Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/26/09/61650635/united-natural-foods-abm-industries-and-3-stocks-to-watch-heading-into-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","BK4007","IE00B2B36J28.USD","LU0708995401.HKD","FXG","LU0070302665.USD","IE0009355771.USD","BK4113","BK4578","IE00BFTCPJ56.SGD","CASY","LU0109391861.USD","NVS","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0320765489.SGD","IE0002141913.USD","DECU","BK4588","RGLO","IE00BJT1NW94.SGD","CODX","PMDE","GXDW","BK4532","LU0320765059.SGD","BK4102","IE0009354923.USD","PPH","UNFI","VGFPF","LU1267930730.SGD","ABM","BK4082","FEBU","LU1878469433.USD","JOYT","VOTE","BK4568","BK4585","LU0672654240.SGD","LU0208291251.USD","MEDX","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665034034","title":"Novartis's Latest Trial Failure is Second Pipeline Setback in a Row","url":"https://stock-news.laohu8.com/highlight/detail?id=2665034034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665034034?lang=en_us&edition=fundamental","pubTime":"2026-09-08 14:46","pubTimestamp":1788849960,"startTime":"0","endTime":"0","summary":"0646 GMT - Novartis just suffered its second major pipeline setback in the past week after a drug candidate it acquired through its recent $12 billion Avidity Biosciences deal failed in a late-stage study, Vontobel's Stefan Schneider says in a research note. News that experimental drug del-desiran missed the goal in a trial for neuromuscular disease myotonic dystrophy type 1 comes after the Swiss pharmaceutical company last week reported disappointing results for cardiovascular medicine pelacarsen. Vontobel had forecast annual peak sales from del-desiran at $3 billion, with a 50% chance of reaching them, and now removes this forecast from its model. As a result, Vontobel cuts its target price on Novartis stock to 125 Swiss francs from 128 francs. Novartis shares closed at 125.46 francs on Monday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0070302665.USD","LU0320765489.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4588","BK4585","IE0002141913.USD","IE00B2B36J28.USD","BK4007","MEDX","PPH","BK4532","LU0211331839.USD","BK4578","IE00B4R5TH58.HKD","LU0208291251.USD","IE00BJT1NW94.SGD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193693103","title":"European Equities Remain Flat as Energy Gains Offset by Pharma Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1193693103","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193693103?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:30","pubTimestamp":1788798644,"startTime":"0","endTime":"0","summary":"European markets closed Monday with little movement, as rising crude prices and a sharp decline in a major pharmaceutical firm counterbalanced each other. The benchmark Stoxx Europe 600 index...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENHI","TDI","FDEV","FIEE","IEV","AIVI","EPV","IE0002141913.USD","IDUB","XEUR","SPEU","BBIN","IE00BJT1NW94.SGD","XES","IFV","IEO","PPIE","QBIV","RFEU","IEUR","BRIE","PIEQ","YDEC","IEFA","GIEQ","JDVI","TACN","PQIN","IDJN","BK4504","BK4585","OIH","STXI","INOV","NIHI","IFEB","OILK","REFA","ISWN","OPPE","BK4588","IGGY","JHMD","QEFA","EPIN","BWET","YSEP","PTEU","EURL","FDT","PIZ","SSXU","USL","BK4581","HEFA","GSEU","IJAN","PPH","PZIV","XLEX","ESIM","CWI","EFO","MFSI","DTAN","RAYD","RDMX","JPIN","PGRI","UPV","NUDM","FSZ","INTF","XEML","IAPR","IDEQ","FFDI","VEA","PTIN","FEDM","AVNM","MFDX","GLBL","IDEC","UAE","XW","RODE","KOKU","DBEF","FTXN","IVAL","CGXU","AVIV","JIRE","TLTD","PXE","FEOE","FEZ","BK4167","ISEP","BK4582","DFIC","FEP","IFLR","IOCT","ITOL","IE00B4R5TH58.HKD","GXUS","CGIE","ICOW","URTH","OILU","DMXF","NVS","ICPY","AVDE","CGIC","DDWM","GUSH","BK4532","GLOF","EAFG","SCHF","GSID","IMOM","PXF","TOK","PXJ","BK4534","FLEE","VOOV","ILOW","EWN","FENI","BKCI","EFAX","IDMY","VNIE","BK4570","LU0208291251.USD","AVSD","IE00BFTCPJ56.SGD","OILT","TPOR","VGK","DEEF","IMTM","DUG","IE0009355771.USD","ISDX","BK4007","VIDI","QLVD","IE00B2B36J28.USD","JANI","FINT","IDME","DBO","BUFY","DFAX","LU0211331839.USD","DFAI","BKIE","SDOG","BBEU","IQLT","EFA","TPIF","BINV","ACWX","YMAR","IE00BJJMRZ35.SGD","IXUS","JULI","BNO","EUDG","IMFL","MOTI","QBIF","TILC","DRIP","EASG","TOUS","ARLI","RODM","USOI","WCMG","IXC","PDEV","IBUF","EFZ","WWJD","RFDI","HAWX","IMAR","UIVM","DIG","USE","BK4550","FHIL","WCMI","TLCI","HFXI","ERX","IQSI","CVIE","DBE","SPXT","BK4578","DBC","VEU","DINT","VDE","DWMF","APIE","NBIE","OEFA","UGA","LU0070302665.USD","IJUN","BK4020","IDMO","BAIV","VEFA","TIIV","WEEI","SEIE","IVSI","DRLL","LU0320765489.SGD","DXIV","CEFA","IQDF","SPDW","TXUE","DBEU","IAUG","GSIE","IDEV","IMAY","MEDX","IJUL","RINT","WTIU","OAIM","PEJ","BUFI","OVF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665317041","title":"Gilead Sciences (GILD) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2665317041","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665317041?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:25","pubTimestamp":1788798346,"startTime":"0","endTime":"0","summary":"Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences today and set a price target of $160.00. Breen covers the Healthcare se...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-receives-a-buy-from-bernstein-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-receives-a-buy-from-bernstein-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1839511570.USD","LU2112291526.USD","IBB","LU1674673428.USD","LU1571399168.USD","BIB","LABU","LU1778281490.HKD","LU0234570918.USD","MEDI","IE00B7SZLL34.SGD","GILD","LU2089984988.USD","LU1585245621.USD","XLV","LU1934455863.HKD","LU1934455194.USD","LU2324357040.USD","LU0823416689.USD","SG9999015978.USD","LU2468319806.SGD","BK4566","BK4585","SG9999015945.SGD","LU0289739699.SGD","SG9999015952.SGD","BK4139","LU0965508806.USD","TMED","BK4578","BK4550","IE00BZ1G4Q59.USD","BMED","LU0882574055.USD","IE00BSNM7G36.USD","BBH","IE00BKVL7J92.USD","XBI","IE00B3T34201.USD","BK4588","LU1066051498.USD","IE00B19Z3B42.SGD","TBXU","LU0122379950.USD","IE0002270589.USD","LU0114720955.EUR","BK4581","IBBQ","LU1037948541.HKD","LU1934455277.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665317208","title":"Novartis AG Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2665317208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665317208?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:15","pubTimestamp":1788797700,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  dropped 3.2% to CHF125.46 Monday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 0.8% to 14,279.38.Novartis AG closed CHF7.22 short of its 52-week high of CHF132.68, which the company achieved on September 3, 2026.Trading volume was 3,077,526, compared to the 50-day average trading volume of 2,290,037.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B2B36J28.USD","MEDX","IE00BJJMRZ35.SGD","BK4578","PPH","LU0211331839.USD","LU0320765489.SGD","BK4532","IE0009355771.USD","LU0070302665.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0208291251.USD","BK4007","BK4588","NVS","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665176793","title":"Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321","url":"https://stock-news.laohu8.com/highlight/detail?id=2665176793","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665176793?lang=en_us&edition=fundamental","pubTime":"2026-09-07 23:20","pubTimestamp":1788794419,"startTime":"0","endTime":"0","summary":"After Novartis (NVS) reported that pelacarsen’s Phase 3 HORIZON study failed to demonstrate a statistically significant reduction in major adverse ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-says-novartis-news-increases-likelihood-crispr-prioritizes-next-gen-ctx321-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-says-novartis-news-increases-likelihood-crispr-prioritizes-next-gen-ctx321-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4588","IE0002141913.USD","BK4578","PPH","NVS","BK4532","LU0320765489.SGD","IE00BJJMRZ35.SGD","LU0208291251.USD","IE0009355771.USD","MEDX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0070302665.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665552317","title":"Citi sees limited immediate downside for Ionis after pelacarsen failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2665552317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665552317?lang=en_us&edition=fundamental","pubTime":"2026-09-07 23:15","pubTimestamp":1788794109,"startTime":"0","endTime":"0","summary":"After Ionis’ (IONS) partner Novartis (NVS) disclosed that the pelacarsen Phase 3 Lp(a)HORIZON study failed to meet its primary endpoint of cardiova...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-sees-limited-immediate-downside-for-ionis-after-pelacarsen-failure-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-sees-limited-immediate-downside-for-ionis-after-pelacarsen-failure-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211331839.USD","BK4588","NVS","BK4007","PPH","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","IONS","MEDX","IE00B2B36J28.USD","LU0208291251.USD","IE00B4R5TH58.HKD","IE0009355771.USD","BK4139","IE0002141913.USD","BK4585","BK4532","BK4578","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311682","title":"BofA sees low single-digit percentage downside for Novartis on pelacarsen miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311682","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311682?lang=en_us&edition=fundamental","pubTime":"2026-09-07 20:00","pubTimestamp":1788782433,"startTime":"0","endTime":"0","summary":"After Novartis (NVS) announced pelacarsen missed its primary endpoint of reducing cardiovascular events in the Phase 3 HORIZON study, BofA sees low...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bofa-sees-low-single-digit-percentage-downside-for-novartis-on-pelacarsen-miss-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bofa-sees-low-single-digit-percentage-downside-for-novartis-on-pelacarsen-miss-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","BK4578","IE00BJT1NW94.SGD","LU0208291251.USD","BK4007","LU0070302665.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4532","PPH","MEDX","BK4585","LU0211331839.USD","BK4588","IE00B2B36J28.USD","LU0320765489.SGD","IE0009355771.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665572390","title":"Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665572390","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665572390?lang=en_us&edition=fundamental","pubTime":"2026-09-07 16:03","pubTimestamp":1788768180,"startTime":"0","endTime":"0","summary":"Novartis shares fell after the Swiss drugmaker said an experimental medicine failed to reduce cardiovascular risk in a late-stage clinical trial.Shares in Novartis were down 3.2% in European morning t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0320765489.SGD","PPH","IE00BJT1NW94.SGD","LU0070302665.USD","MEDX","BK4007","BK4588","BK4578","LU0211331839.USD","BK4532","NVS","LU0208291251.USD","BK4585","IE0002141913.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665397422","title":"Novartis India to Acquire 'Minipress' Trademarks from Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665397422","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665397422?lang=en_us&edition=fundamental","pubTime":"2026-09-07 15:43","pubTimestamp":1788767020,"startTime":"0","endTime":"0","summary":"BRIEF-Novartis India To Acquire 'Minipress' Trademarks From PfizerSept 7 (Reuters)-Novartis India LtdNOIN.BO:TO ACQUIRE 'MINIPRESS' TRADEMARKS FROM PFIZERSource text:ID:nBSE74jJ9yFurther company coverage:NOIN.BO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nFWN44Y00E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","LU0456855351.SGD","LU0058720904.USD","MEDX","BK4007","BK4550","LU0070302665.USD","IE00BBT3K403.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2596442595.SGD","BK4578","IE00B19Z3581.USD","LU0225284248.USD","SGXZ57979304.SGD","BK4568","BK4533","BK4532","SG9999001176.SGD","LU0122379950.USD","LU0306806265.USD","SG9999003800.SGD","IE00BLSP4452.SGD","NVS","LU0211331839.USD","SG9999002224.SGD","BK4588","LU1057294990.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU1894683348.USD","LU0225771236.USD","IE00B19Z3B42.SGD","BK4599","LU1066051498.USD","BK4592","LU0321505439.SGD","LU1883839398.USD","LU0985481810.HKD","SG9999013999.USD","LU0306807586.USD","BK4581","IE00B2B36J28.USD","BK4585","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE000M9KFDE8.USD","LU0289739699.SGD","LU0321505868.SGD","IE00BLSP4239.USD","LU0868494617.USD","LU0170899867.USD","LU1894683264.USD","IE0002270589.USD","IE00B3T34201.USD","OZEM","PFE","LU1023059063.AUD","PPH","BK4534","SG9999001176.USD","SG9999002232.USD","SG9999011175.SGD","IE00BJT1NW94.SGD","LU0208291251.USD","LU1066053197.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104786890","title":"Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1104786890","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104786890?lang=en_us&edition=fundamental","pubTime":"2026-09-07 15:22","pubTimestamp":1788765738,"startTime":"0","endTime":"0","summary":"Swiss pharma giant Novartis AG (NVS.US) has suffered another clinical trial setback, marking the second high-profile candidate to fail in late-stage studies within a single week. The latest casualty...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","IE00BJT1NW94.SGD","PJP","BK4534","BK4588","LU1571399168.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","BK4585","BK4581","LU1983299246.USD","BBH","LU0208291251.USD","IE00B4R5TH58.HKD","BK4578","IE00BFTCPJ56.SGD","LU2242652126.USD","BIB","LU2242646821.SGD","TBXU","BK4532","IBB","NVS","LU2089984988.USD","LU0058720904.USD","LU0320765992.SGD","LU0289739699.SGD","LU0122379950.USD","LU1023059063.AUD","LU1057294990.SGD","SG9999001440.SGD","IE00B2B36J28.USD","BK4139","LU0109394709.USD","BK4007","IE0002141913.USD","AMGN","LU0211331839.USD","LU0889565916.HKD","IE0009355771.USD","PPH","LU0868494617.USD","LU0320765489.SGD","IBBQ","BK4566","LU0070302665.USD","LU1061106388.HKD","PBE","MEDX","BK4599","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392965","title":"Novartis Heart-Trial Failure Could be Mitigated by Investor Caution","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665392965?lang=en_us&edition=fundamental","pubTime":"2026-09-07 15:04","pubTimestamp":1788764640,"startTime":"0","endTime":"0","summary":"0703 GMT - An experimental Novartis medicine missed the target in a late-stage clinical trial, but the hit to the Swiss drugmaker's share price could be mitigated by investors' skepticism about the study, analysts at Citi say in a research note. The drug, pelacarsen, reduced the levels of a fatty particle in the blood known as Lp, but this didn't translate to clinical outcomes, Citi says. \"We think market expectations of a positive trial were already cautious, with question marks around the magnitude of benefit and difficulty in commercialization even if the study had met the endpoint, which we think could limit the impact of the trial failure on the share price,\" the analysts say.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","PPH","NVS","IE00B4R5TH58.HKD","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4588","LU0070302665.USD","BK4585","LU0208291251.USD","IE00B2B36J28.USD","BK4578","BK4007","IE00BJJMRZ35.SGD","MEDX","LU0211331839.USD","IE0002141913.USD","BK4532","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":105,"code":"91000000","status":"200"}]}}